Prevalence and Associated Factors of Anxiety and Depression Among Patients with Type 2 Diabetes in Kerman, Southern Iran

This article was published in the following Dove Press journal:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Tania Dehesh¹

Paria Dehesh²

Shahla Shojaei³

¹Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran; ²Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; ³College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Purpose: Depression and anxiety are common disorders in patients suffering from type 2 diabetes. These disorders can lead to premature morbidity, exacerbate disease complications, make patients suffer more, and increase health-care costs. As diabetes has increased worldwide recently, it is necessary to reduce the prevalence of factors that are associated with depression and anxiety in diabetes patients. This study aimed to assess the prevalence of anxiety and depression and to identify their associated factors, including metabolic components among people with type 2 diabetes.

Patients and Methods: We performed a cross-sectional study in 1500 patients with type 2 diabetes in Kerman, in the southern part of Iran. The prevalence of depression and anxiety was estimated using the Beck Depression Inventory and the Hamilton Anxiety questionnaires, respectively. After calculating the proportions of depression and anxiety, univariate logistic regression was performed. Factors whose *P*-values were smaller than 0.2 in univariate logistic regression were included in multiple logistic regression for confounder adjustments. The analysis was performed using SPSS version 20.

Results: The rates of depression and anxiety were 59% (95% CI: 54.48–63.12) and 62% (95% CI: 59.51–66.27), respectively. Factors found to be independently associated with anxiety were high FBS, high LDL-C, high TG, hypertension, complications, low physical activity. Factors found to be independently associated with depression were female gender, older age, high BMI, high FBS, high LDL-C, low HDL-C, high TG, high HbA1c, hypertension, and low physical activity. Complications were independently associated with anxiety but not with depression. Female gender, older age, high BMI, low HDL-C, and high HbA1c were independently associated with depression but not with anxiety.

Conclusion: Current findings demonstrated that a large proportion of patients with type 2 diabetes suffer from depression and anxiety. This study also identified factors associated with these disorders. Controlling some metabolic variables will decrease the prevalence of these disorders and improves clinical remedy and quality of life in patients with type 2 diabetes.

Keywords: anxiety, depression, type 2 diabetes, Hamilton questionnaire, Beck questionnaire

Introduction

The prevalence of diabetes is increasing globally. Almost 285 million people are suffering from diabetes, and this number is expected to be increased to 438 million by 2030.¹

Diabetic patients suffer from anxiety and depression almost twice as much as the general population.² In the general population, the 12-month prevalence of anxiety and depression was 18% and 10%, respectively.³ The prevalence of anxiety and depression disorders in type 2 diabetes is approximately 60% higher than the

Correspondence: Paria Dehesh
Email Paria_dehesh@yahoo.com

general population.⁴ The complications of anxiety and depression affect all populations globally, but more than two-thirds of people who are suffering from these two disorders are living in developing countries.⁵ Previous studies show that anxiety and depression have an important negative impact on diabetic patients' abilities.⁶ Diabetes patients that have depression and anxiety disorders usually are less physically active and show less desire to take their prescribed medications.⁷ Recent studies show that diabetes and depression are associated with premature mortality; these results confirm that the combination of these two diseases will significantly increase the suffering and costs of patients.⁸

The prevalence of Type 2 diabetes is about 85.5% of all type of diabetes in Iran.⁹ The prevalences of depression and anxiety in Iranian patients with Type 2 diabetes are about 61.8% and 64.5%, respectively.¹⁰ Previous studies show that being female, having at least secondary higher cycle education, lower socioeconomic status, smoking, poorer blood sugar control,¹¹ less physical inactivity, obesity, and excessive alcohol drinking¹² are associated factors of depression and anxiety in diabetes patients. Another study demonstrated the role of hypertriglyceridemia and hypertension in increasing these disorders.¹³ Some studies tried to find an association between dyslipidemia other metabolic components with depression or anxiety.¹⁴ Cholesterol is an important component of the central nervous system, especially in cell membranes, and operates as the second messenger system in the brain that is related to mood stabilization.¹⁵ Anxiety is also related to an abnormal level of blood glucose, mainly among patients with severe anxiety.¹⁶

Management of anxiety and depression by controlling influential metabolic variables can be helpful in diminishing illness suffering, which leads to the improvement of patients, while reducing the costs of patients and health services.¹⁷

Despite inconsistent findings in previous studies about the association between blood metabolic variables and the severity of anxiety and depression in diabetes patients,¹⁸ there is limited information about the association among people with diabetes in developing countries, such as Iran.

This study aimed to assess first the prevalence of anxiety and depression in a large outpatient sample of people with type 2 diabetes, and second the associated factors of anxiety and depression among patients with type 2 diabetes in southern parts of Iran.

Materials and Methods

Subjects

A total of 1500 diabetes patients 18–75 years of age were enrolled in this case-control study between August and November 2018. The presence of diabetes was defined as a fasting plasma glucose value >7.0 mmol/L (FBS >126 mg/dL).

To ensure the heterogeneity of the sample, patients were recruited from several clinical laboratories. Inclusion criteria included: Iranian nationality; a diagnosis of Type 2 diabetes at least 6 months prior to the start of the study, age 18–75 years, and not taking any medication that influences glucose tolerance (thiazide diuretics, beta-blockers, steroids, psychopharmacologic medications, particularly antipsychotics, tricyclic antidepressants, or serotonin reuptake inhibitors) apart from insulin or sulfonylureas. Exclusion criteria were: diagnosis of an underlying disease such as renal disease, history of cardiovascular disease (myocardial infarction or coronary revascularization), and cerebrovascular disease (stroke or carotid endarterectomy). Individuals with unknown or pre-diabetes status were also omitted from the study. These patients referred to laboratories in order to check their blood test. All participants were asked to complete two questionnaires. Illiterate patients completed questionnaires by face to face interview in the presence of a witness.

Full confidentiality of the data collected was ensured to all the participants and all interviews were done after the participant's consent. The study was approved by the local ethics committee of the Kerman University of Medical Sciences (reference number: IR.KMU.REC.1397.174), and all participants provided their written informed consent prior to the beginning of the study. This study was conducted in accordance with the Declaration of Helsinki.

The following demographic, clinical, and laboratory data were recorded or determined for each patient at the moment of the inclusion in the study: age, gender, marital status education, alcohol dependency, cigarette smoking, and complications (retinopathy, cardiomyopathies, nephropathies, and neuropathies associated with diabetes mellitus were considered as complications), depression and anxiety, weight, height, body mass index (BMI), blood pressure (BP), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).

Psychiatry Measurements

The Beck Depression Inventory (BDI) questionnaire is one of the most common questionnaires that is used for

screening depression in the general population. The BDI-II, the Persian version, is used in this study, and the validity and reliability of the Persian version has been defined in the previous study.¹⁹ It contains 21 items, and each question has 4 options to answer, showing the severity of depressive symptoms, and a total score ranging between 0 and 63. Thereafter, 0–13 points indicate none or minimal, 14–19 points mild, 20–28 points moderate, and 29–63 points severe depressive symptoms.²⁰ We considered a cut-off scale of 18 to study the population. This cut-off scale was previously used in other studies.²¹

The Hamilton Anxiety (HA) questionnaire is a 14-item clinician-rated instrument designed to assess and quantify the severity of anxiety. Each item is rated on a five-point Likert-type scale ranging from 0 to 4. Although the scale assesses a broad range of symptoms, it is most frequently used to assess the severity of generalized anxiety disorder. HA is comprised of psychic and somatic subscales. The psychic subscale (items 1–6 and 14) evaluates the subjective cognitive and affective complaints of anxiety (anxious mood, tension, fears, difficulty concentrating); it is particularly useful in assessing the severity of generalized anxiety disorder. The somatic component (items 7–13) emphasizes features of general anxiety disorder such as autonomic arousal, as well as respiratory, gastrointestinal, and cardiovascular symptoms. Validity and reliability of the Persian version were defined in the previous study.²² A score of 14 considered as a threshold for clinically significant anxiety.²³

Laboratory Measurements

Blood samples were taken from each patient at 8:00 a.m. Serum FBS, triglyceride, cholesterol, HDL-C, and LDL-C levels were determined by BS-300MINDRAY (Shenzhen Mindray Biomedical Electronics Co., Shenzhen, China) by Roche kits (Penzberg, Germany). Arterial blood pressure (BP) was determined with a calibrated sphygmomanometer, aneroid type, and a stethoscope. Patients were seated for 10 min before the pressure was taken. BP measurements were carried out on the left and right arms and the average of two measurements was recorded as a BP value. Measurements were taken by skilled nurses.

Statistical Analysis

Descriptive statistics were computed and reported for all the variables. Bivariable and multivariable logistic regressions were performed to identify independent predictors of depression and anxiety. Variables with a *P*-value of less

than 0.2 in the bivariable logistic regression were entered into the multivariable regression model.²⁴ The variance inflation factor was assessed for multicollinearity between predictors, and no multicollinearity was detected. The final model was selected through a backward selection approach based on the likelihood ratio test and the lowest Akaike's information criteria value. Potential interaction effects were checked at the significance level of 0.1, and none of them were significant. Crude and adjusted odds ratio (OR) with 95% confidence interval were reported. Hosmer–Lemeshow goodness of fit was run on the fully adjusted anxiety and depression models to check for an adequate fit of the data. The level of significance was set at 0.05 (two-tailed). All analyses were performed using the Statistical Package for Social Science (SPSS) version 20 for Windows.

Results

From this sample, the rates for depression and anxiety were 59% (95% CI: 54.48–63.12) and 62% (95% CI: 59.51–66.27), respectively. In this sample, the larger group was formed of females (51.3%). Most of them were married (75.3%) and mainly employed (62.0%). The socio-demographic characteristics of the participants are summarized in Table 1. The mean age was 47.12±12.52 years with arrange of 18–79 years old. The mean level of education was 8.91±5.13 years. Eighteen percent of patients had not received formal education or were illiterate. The mean body mass index was 27.81±5.21 with a range of 17–48. The average glucose level was 174.42±73.32 mg/dL, with a range of 70–500 mg/dL. The mean systolic BP was 121.00±13.11 (range 90–180) and the corresponding average diastolic BP was 81.13±10.72 (range 60–130). The mean HbA1c was 7.8±1.6 (range 7.1–8.2), mean LDL-C was 111.5±34.7, mean TG was 1.6±1.5 (mmol/L), and mean HDL-C was 1.5±0.4 (mmol/L). When we analyzed anxiety the average score was 17.87±11.06 (range 1–39), whereas the mean score for depression was 15.5±9.6, with a range of 1–49.

Table 2 summarizes the results of univariate and multivariate analyses of characters and metabolic variables for associations with anxiety. The variables that showed a significant positive association with increasing anxiety were high FBS level, high LDL-C, high TG, high HbA1c, hypertension, presence of complications, and lack of physical activity. In multivariable logistic regression, when univariate result was adjusted for confounding variables, high FBS level [AOR=1.38,95], high LDL-C [AOR=1.54,95], high

Table 1 Population Characteristics According to Demographic, Metabolic and Psychopathology Status of Patients with Type 2 Diabetes

		Number	Percent
Gender	Male	730	48.7
	Female	770	51.3
Marital Status	Married	1130	75.3
	Single	210	14.0
	Widowed	110	7.3
	Separated/ divorced	50	3.3
Occupation	Employed	930	62.0
	Unemployed	570	38.0
Age (in years)	Up to 50	1113	74.2
	≥50	387	25.8
Education	Up to 6 years	640	42.7
	>6 years of schooling	860	57.3
Cigarette Smoking (Dependency)	Yes	550	36.6
	No	950	63.4
Alcohol Abuse/ Dependency	Yes	398	26.6
	No	1102	73.4
Insulin Use	Yes	390	26.0
	No	1110	74.0
High BMI	Yes	217	14.6
	No	1283	85.4
High FBS Level (mg/dl)	Yes	1281	85.4
	No	219	14.6
High LDL-C (mmol/L)	Yes	295	19.8
	No	1205	80.2
Low HDL-C (mmol/L)	Yes	195	12.9
	No	1305	87.1
High TG (mmol/L)	Yes	1216	79.0
	No	284	19.0
HbA1c	Yes	1261	84.1
	No	239	15.9
Hypertension	Yes	602	39.1

(Continued)

Table 1 (Continued).

		Number	Percent
	No	898	60.9
Anxiety	With anxiety	930	62.0
	Without anxiety	570	38.0
Depression	With depression	885	59.0
	Without depression	615	41.0
Complications	Yes	75	4.2
	No	1425	95.8
Physical Activity	Yes	653	43.5
	No	847	56.5

Notes: High FBS: >120 (mg/dL); high BMI: ≥25 kg/m²; low HDL-C: HDL-C <1.03 (mmol/L) for men and <1.3 (mmol/L) for woman; high LDL-C: LDL-C ≥4.13 (mmol/L); high TG: ≥1.7 mmol/L; high HbA1c: HbA1c >0.7mmol/hypertension: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.

TG [AOR=1.2395], hypertension [AOR=1.5295], complication [AOR=1.4295] and lack of physical activities [AOR=1.38,95] and were significantly associated with higher anxiety score.

Table 3 summarizes the results of univariate and multivariate analyses of characteristics and metabolic variables of associations with depression. The variables that showed a significant positive association with increasing depression were female gender, high age, BMI, high FBS level, high LDL-C, low HDL-C, high TG, high HbA1c, hypertension, and lack of physical activity. In multivariable logistic regression, when univariate result was adjusted for confounding variables, female gender [AOR=1.3895], high age [AOR=1.3595], BMI [AOR=1.3195], high FBS level [AOR=1.5195], high LDL-C [AOR=1.42,95], low HDL-C [AOR=1.4895], high TG [AOR=1.3995], high HbA1c [AOR=1.5495], hypertension [AOR=1.3995], and lack of physical activities [AOR=1.6495], were significantly associated with higher depression score.

Discussion

This study estimated the prevalence of depression and anxiety in a type 2 diabetic population in Kerman located in the southern part of Iran. This study showed that low physical activity, diabetes complications, high LDL-C, high TG, high FBS level, and hypertension are

Table 2 Association Between Demographic and Metabolic Variables and Anxiety in Patients with Type 2 Diabetes

Variables	Levels	With Anxiety	Without Anxiety	OR (95% CI)	P	AOR (95% CI)	P
Gender N (%)	Male Female	388 431	342 339	Ref. 1.12 (0.61–1.17)	0.18	Ref. 1.21 (0.81–1.63)	0.15
Marital Status	Married Single Widowed Separated/divorced	618 126 58 27	512 84 52 23	Ref. 0.79 (0.57–1.23) 1.07 (0.98–1.43) 1.02 (0.89–1.18)	0.32 0.31 0.29	–	–
Occupation	Employed Unemployed	430 289	500 281	Ref. 1.19 (0.77–1.49)	0.24	–	–
Age (in years)	Up to 50 ≥50	523 187	590 200	Ref. 1.05 (0.78–1.41)	– 0.33	–	–
Education	Up to 6 years >6 years	358 473	282 387	Ref. 0.98 (0.67–1.48)	0.26	–	–
Cigarette Smoking	No Yes	531 250	419 300	Ref. 0.65 (0.31–2.11)	0.14	–	–
Alcohol Dependency	No Yes	465 130	637 268	Ref. 0.66 (0.38–1.62)	0.23	–	–
Insulin Use Drug Treatment	No Yes	233 86	877 304	Ref. 1.07 (0.54–1.31)	0.34	–	–
High BMI	No Yes	328 50	955 167	Ref. 0.87 (0.48–1.38)	0.32	–	–
High FBS Level (mg/dl)	No Yes	112 767	107 514	Ref. 1.42 (0.34–1.17)	0.03*	Ref. 1.38 (1.05–2.13)	0.04*
High LDL-C (mmol/L)	No Yes	121 30	1084 165	Ref. 1.64 (1.78–2.56)	0.02*	Ref. 1.54 (1.14–2.15)	0.03*
Low HDL-C (mmol/L)	No Yes	453 77	852 118	Ref. 1.22 (1.03–2.08)	0.11	Ref. 1.09 (0.88–1.94)	0.32
High TG (mmol/L)	No Yes	54 329	230 887	Ref. 1.58 (1.17–2.09)	0.03*	Ref. 1.23 (1.06–1.72)	0.04*
High HbA1c	No Yes	43 302	196 959	Ref. 1.44 (1.11–1.72)	0.04*	Ref. 1.09 (0.85–1.42)	0.13
Hypertension	No Yes	342 338	556 264	Ref. 2.08 (1.64–2.31)	0.02*	Ref. 1.52 (1.18–2.03)	0.03*
Complications	No Yes	698 45	727 30	Ref. 1.56 (1.08–1.79)	0.03*	Ref. 1.42 (1.11–1.62)	0.01*
Physical Activity	Yes No	290 467	343 380	Ref. 1.45 (1.01–2.22)	0.02*	Ref. 1.38 (1.08–1.71)	0.01*

Notes: Ref: reference category; P: P-value; high FBS: >126 (mg/dL); high BMI: ≥25 kg/m²; Low HDL-C: HDL-C <1.03 (mmol/L) for men and <1.3 (mmol/L) for woman; high LDL-C: LDL-C ≥4.13 (mmol/L); high TG: ≥1.7 mmol/L; high HbA1c: HbA1c >0.7mmol/hypertension: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. *Significant P-value.

Abbreviations: OR, odds ratio; AOR, adjusted odds ratio.

positively associated with high anxiety scores. High Age, high BMI, female gender, low physical activity, high LDL-C, low HDL-C, high TG, high FBS level, high HbA1c, and hypertension are positively associated with depression.

Several studies demonstrated that the development of co-morbid anxiety and/or depression in diabetic people leads to increased disease severity, complications, work disability, poor quality of life and increased use of medical services, and higher burden of health-care costs.⁸

Table 3 Association Between Demographic and Metabolic Variables and Depression in Patients with Type 2 Diabetes

Variables	Levels	With Anxiety	Without Anxiety	OR (95% CI)	P	AOR (95% CI)	P
Gender N (%)	Male	329	401	Ref.	0.18	Ref. 1.38 (1.09–2.04)	0.04*
	Female	385	385	1.22 (0.42–1.57)			
Marital Status	Married	583	547	Ref.	0.37	–	–
	Single	120	90	1.26 (0.52–1.99)			
	Widowed	56	54	0.97 (0.51–1.39)			
	Separated/divorced	25	25	0.93 (0.45–1.21)			
Occupation	Employed	389	541	Ref.	0.41	–	–
	Unemployed	262	308	1.17 (0.61–1.37)			
Age (in years)	Up to 50	421	692	Ref.	0.33	Ref. 1.35 (1.12–1.89)	0.01*
	≥50	179	208	1.43 (0.68–1.88)			
Education	Up to 6 years	226	414	Ref.	0.37	–	–
	>6 years	300	560	0.98 (0.39–1.35)			
Cigarette Smoking	No	238	206	Ref.	0.19	Ref. 1.09 (0.63–1.13)	0.53
	Yes	506	444	0.98 (0.77–1.62)			
Alcohol Dependency	No	260	842	Ref.	0.02*	Ref. 1.11 (0.48–1.64)	0.19
	Yes	125	273	1.49 (0.97–1.89)			
Insulin Use Drug Treatment	No	82	308	Ref.	0.41	–	–
	Yes	228	882	0.97 (0.58–1.51)			
BMI	No	343	940	Ref.	0.04*	Ref. 1.31 (1.15–1.87)	0.01*
	Yes	74	143	1.42 (0.86–2.03)			
High FBS Level (mg/dl)	No	119	100	Ref.	0.01*	Ref. 1.51 (1.08–2.21)	0.02*
	Yes	692	380	1.54 (0.71–2.13)			
High LDL-C (mmol/L)	No	98	1107	Ref.	0.02	Ref. 1.42 (1.14–2.75)	0.03*
	Yes	54	241	1.61 (1.18–2.29)			
Low HDL-C (mmol/L)	No	148	1057	Ref.	0.02*	Ref. 1.48 (1.22–3.08)	0.001*
	Yes	54	241	1.63 (1.11–2.83)			
High TG (mmol/L)	No	51	233	Ref.	0.03*	Ref. 1.39 (1.06–2.31)	<0.001*
	Yes	306	910	1.53 (1.14–2.21)			
High HbA1c	No	37	202	Ref.	0.02*	Ref. 1.54 (1.12–2.03)	0.02*
	Yes	284	977	1.59 (1.08–2.11)			
Hypertension	No	387	511	Ref.	0.01*	Ref. 1.39 (1.09–2.17)	0.02*
	Yes	321	281	1.51 (1.13–2.05)			
Complications	No	705	720	Ref.	0.04*	Ref. 1.06 (0.85–1.31)	0.16
	Yes	42	33	1.31 (1.09–1.92)			
Physical Activity	Yes	366	481	Ref.	0.01*	Ref. 1.64 (1.18–2.22)	0.01*
	No	387	266	1.92 (1.11–2.02)			

Notes: Ref: reference category; P: P-value; High FBS: >126 (mg/dL); high BMI: ≥25 kg/m²; Low HDL-C: HDL-C <1.03 (mmol/L) for men and <1.3 (mmol/L) for woman; high LDL-C: LDL-C ≥4.13 (mmol/L); high TG: ≥1.7 mmol/L; high HbA1c: HbA1c >0.7mmol/hypertension: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg; *Significant P-value.

Abbreviations: OR, odds ratio; AOR, adjusted odds ratio.

In this study, the prevalence of anxiety and depression was estimated at 59% and 62%, respectively. Two studies have analyzed its prevalence of depression in diabetic patients in Kerman, and their results were published in a systematic review study.¹⁰ According to the result of this

systematic review, these two research projects focused only on prevalence of depression in diabetes patients in Kerman and they did not report anxiety prevalence. The two studies exhibited a similar depression prevalence of 57% and 61%. However, their sample sizes were small (n=300 and 150,

respectively). In the present study, the sample size was increased to 1500 diabetic patients. In addition, we analyzed the frequency of anxiety in these patients. To our knowledge, this is the first study analyzing both depression and anxiety in diabetes patients in the southern part of Iran. However, we found a higher prevalence than the one reported in those studies. In fact, recent studies have shown a lower prevalence in under-developed countries.^{1,25}

We observed a positive association between diabetes complications and higher anxiety, but not with depression. This result is in line with the result of a previous study.²⁶ Also, against the result of this study, a previous study showed that there is an association between neuropathy as a complication of diabetes and depression.²⁷

This study showed that women had higher depression score compared to men. Several previous studies confirmed a similar result, according to which females experience significantly more depression in general populations²⁸ and among people with diabetes. A possible explanation is that women experience gender-specific events such as menarche cycles and childbirth, which expose them to handle several works and emotion at a time. This situation makes them more emotional and sensitive in comparison to men.²⁹

This study also showed that age is an independent factor for depression. This result is in accordance with a previous report that showed a significant association between age and depression and other psychological disorders.²⁹ This may be due to more isolation being experienced in older age that may lead to the development of psychological conditions.³⁰

It is well known that physical activity is a protective barrier against depression and the development of other psychological illnesses.³¹ Furthermore, the negative association between physical activity and anxiety was confirmed among various groups of the population.³² This study proved that physical inactivity had an independent association with depression and anxiety.

In the current research, BMI was found to be independently associated with depression, but not anxiety. This result is in line with previous studies that identified BMI as an independent factor associated with depression among people with diabetes.³³

This study showed a positive effect of high TG on depression and anxiety; this result is inconsistent with the results of a previous study that showed the effect of TG on both disorder types.¹ Another study confirmed the effect of higher TG on increasing depression in type 2 diabetes patients.³⁴ This may be due to the fact that comorbid anxiety in patients with depression may increase the levels of circulating catecholamines and

increase the lipoprotein lipase activity, thus elevating the serum cholesterol and triglyceride concentrations.³⁵

FBS was associated with depression and anxiety, which was also confirmed in previous studies.²⁶ HbA1c was associated with depression, but not with anxiety. This result is in line with the result of the previous study that confirms this effect on depression only.³⁶

Low HDL-C was also associated with increased depression and anxiety, and this result is in line with the results of a previous study conducted in the Netherlands, which confirmed the role of decreasing HLD in anxiety and depression in the general population.³⁷ High LDL-C was associated with depression and anxiety. This result is in line with the result of a previous study in the general population in Iran,³⁸ but disagrees with studies that did not find a significant association between high LDL-C and both disorders.³⁹ The effect of profile lipids could be explained by the fact that depression is associated with cytokine activation, which can impair cholesterol synthesis.⁴⁰ There is also the possibility that cholesterol plays a causal role because it may reduce the availability of serotonin.⁴¹

This study also confirmed the association of hypertension with both depression and anxiety. In a previous study higher diastolic blood pressure was found in female patients with diabetes compared to healthy people, but this was not significant.³⁹

Some limitations can be identified in this study. We did not measure depression and anxiety scores in the general population to compare with patients' scores; our focus was to identify the predictors of depression and anxiety in diabetic patients. The depression and anxiety were measured once; to ensure more precision it is better to measure these scores several times in a period and the average scores must be identified as the final score. Therefore, we suggest that more comprehensive longitudinal studies are necessary to determine the exact effect of predictors on depression and anxiety scores in diabetic patients.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Khuwaja AK, Lalani S, Dhanani R, Azam IS, Rafique G, White F. Anxiety and depression among outpatients with type 2 diabetes: a multi-centre study of prevalence and associated factors. *Diabetol Metab Syndr*. 2010;2(1):72. doi:10.1186/1758-5996-2-72
2. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*. 2001;24(6):1069–1078. doi:10.2337/diacare.24.6.1069

3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593–602. doi:10.1001/archpsyc.62.6.593
4. Ali S, Stone M, Peters J, Davies M, Khunti K. The prevalence of comorbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. *Diabet Med*. 2006;23(11):1165–1173. doi:10.1111/j.1464-5491.2006.01943.x
5. Khuwaja A, Qureshi R, Azam S. Prevalence and factors associated with anxiety and depression among family practitioners in Karachi, Pakistan. *J Pak Med Assoc*. 2004;54(2):45.
6. Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. *Arch Gen Psychiatry*. 2007;64(10):1180–1188. doi:10.1001/archpsyc.64.10.1180
7. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. *Arch Intern Med*. 2000;160(21):3278–3285. doi:10.1001/archinte.160.21.3278
8. Lin EH, Rutter CM, Katon W, et al. Depression and advanced complications of diabetes: a prospective cohort study. *Diabetes Care*. 2010;33(2):264–269. doi:10.2337/dc09-1068
9. Esteghamati A, Larijani B, Aghajani MH, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of national program for prevention and control of diabetes (NPPCD-2016). *Sci Rep*. 2017;7(1):13461. doi:10.1038/s41598-017-13379-z
10. Khalighi Z, Badfar G, Mahmoudi L, Soleymani A, Azami M, Shohani M. The prevalence of depression and anxiety in Iranian patients with diabetes mellitus: a systematic review and meta-analysis. *Diabetes Metab Syndr*. 2019;13(4):2785–2794. doi:10.1016/j.dsx.2019.07.004
11. Lustman P, Clouse R, Freedland K. Management of major depression in adults with diabetes: implications of recent clinical trials. Paper presented at: Seminars in clinical neuropsychiatry; 1998.
12. Atlantis E, Lange K, Goldney RD, et al. Specific medical conditions associated with clinically significant depressive symptoms in men. *Soc Psychiatry Psychiatr Epidemiol*. 2011;46(12):1303–1312. doi:10.1007/s00127-010-0302-3
13. Grimsrud A, Stein DJ, Seedat S, Williams D, Myer L. The association between hypertension and depression and anxiety disorders: results from a nationally-representative sample of South African adults. *PLoS One*. 2009;4(5):e5552. doi:10.1371/journal.pone.0005552
14. Almeida O, Yeap B, Hankey G, Golledge J, Flicker L. HDL cholesterol and the risk of depression over 5 years. *Mol Psychiatry*. 2014;19(6):637. doi:10.1038/mp.2013.113
15. De Berardis D, Conti C, Serroni N, et al. The role of cholesterol levels in mood disorders and suicide. *J Biol Regul Homeost Agents*. 2009;23(3):133.
16. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Prevalence of anxiety in adults with diabetes: a systematic review. *J Psychosom Res*. 2002;53(6):1053–1060. doi:10.1016/S0022-3999(02)00417-8
17. Simon GE, Katon WJ, Lin EH, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. *Arch Gen Psychiatry*. 2007;64(1):65–72. doi:10.1001/archpsyc.64.1.65
18. Takeuchi T, Nakao M, Nomura K, Yano E. Association of metabolic syndrome with depression and anxiety in Japanese men. *Diabetes Metab*. 2009;35(1):32–36. doi:10.1016/j.diabet.2008.06.006
19. Dadfar M, Kalibatseva Z. Psychometric properties of the Persian version of the short Beck depression inventory with Iranian psychiatric outpatients. *Scientifica*. 2016;2016.
20. Kühner C, Bürger C, Keller F, Hautzinger M. Reliabilität und Validität des revidierten Beck-Depressionsinventars (BDI-II). *Nervenarzt*. 2007;78(6):651–656. doi:10.1007/s00115-006-2098-7
21. Toosi F, Rahimi C, Sajjadi S. Psychometric properties of Beck depression inventory-II for high school children in Shiraz City, Iran. *Int J School Health*. 2017;4(3).
22. Abbasi Shavazi M, Razeghi Nasrabad B. Patterns and influencing factors on the interval between marriage and first birth in Iran. *J Popul Assoc Iran*. 2010;5(9):77–105.
23. Bagheri F, Ebrahimzadeh MH, Moradi A, Bidgoli HF. Factors Associated with Pain, Disability and Quality of Life in Patients Suffering from Frozen Shoulder. *Arch Bone Jt Surg*. 2016;4(3):243–247.
24. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. *Am J Epidemiol*. 1993;138(11):923–936. doi:10.1093/oxfordjournals.aje.a116813
25. Balhara YPS, Sagar R. Correlates of anxiety and depression among patients with type 2 diabetes mellitus. *Indian J Endocrinol Metab*. 2011;15(Suppl1):S50. doi:10.4103/2230-8210.83057
26. Tovilla-Zarate C, Juarez-Rojop I, Jimenez YP, et al. Prevalence of anxiety and depression among outpatients with type 2 diabetes in the Mexican population. *PLoS One*. 2012;7(5):e36887. doi:10.1371/journal.pone.0036887
27. Bartoli F, Carrà G, Crocamo C, et al. Association between depression and neuropathy in people with type 2 diabetes: a meta-analysis. *Int J Geriatr Psychiatry*. 2016;31(8):829–836. doi:10.1002/gps.4397
28. Mirza I, Jenkins R. Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review. *BMJ*. 2004;328(7443):794. doi:10.1136/bmj.328.7443.794
29. Khuwaja AK, Kadir MM. Gender differences and clustering pattern of behavioural risk factors for chronic non-communicable diseases: community-based study from a developing country. *Chronic Illn*. 2010;6(3):163–170. doi:10.1177/1742395309352255
30. Ganatra HA, Zafar SN, Qidwai W, Rozi S. Prevalence and predictors of depression among an elderly population of Pakistan. *Aging Ment Health*. 2008;12(3):349–356. doi:10.1080/13607860802121068
31. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. *Prim Care Companion J Clin Psychiatry*. 2004;6(3):104. doi:10.4088/PCC.v06n0301
32. Hong X, Li J, Xu F, et al. Physical activity inversely associated with the presence of depression among urban adolescents in regional China. *BMC Public Health*. 2009;9(1):148. doi:10.1186/1471-2458-9-148
33. Pervene S, Otho MS, Siddiqi MN, Hatcher J, Rafique G. Association of depression with newly diagnosed type 2 diabetes among adults aged between 25 to 60 years in Karachi, Pakistan. *Diabetol Metab Syndr*. 2010;2(1):17. doi:10.1186/1758-5996-2-17
34. Laake J-PS, Stahl D, Amiel SA, et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study. *Diabetes Care*. 2014;37(8):2186–2192. doi:10.2337/dc13-2522
35. Charney DS, Redmond D Jr. Neurobiological mechanisms in human anxiety evidence supporting central noradrenergic hyperactivity. *neuropharmacology*. 1983;22(12):1531–1536. doi:10.1016/0028-3908(83)90122-3
36. Fisher L, Skaff M, Mullan J, Arean P, Glasgow R, Masharani U. A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with type 2 diabetes. *Diabet Med*. 2008;25(9):1096–1101. doi:10.1111/j.1464-5491.2008.02533.x
37. van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Longitudinal relationship of depressive and anxiety symptoms with dyslipidemia and abdominal obesity. *Psychosom Med*. 2013;75(1):83–89. doi:10.1097/PSY.0b013e318274d30f
38. Roohafza H, Sadeghi M, Afshar H, Mousavi G, Shirani S. Evaluation of lipid profile in patient with major depressive disorder and generalized anxiety disorder. *ARYA Atheroscler*. 2010;1(1).

39. Muhtz C, Zyriax B-C, Klähn T, Windler E, Otte C. Depressive symptoms and metabolic risk: effects of cortisol and gender. *Psychoneuroendocrinology*. 2009;34(7):1004–1011. doi:10.1016/j.psyneuen.2009.01.016
40. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. *Diabetes*. 1992;41(Supplement 2):97–101. doi:10.2337/diab.41.2.S97
41. Terao T, Nakamura J, Yoshimura R, et al. Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women. *Psychiatry Res*. 2000;96(2):167–173. doi:10.1016/S0165-1781(00)00197-9

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>